Literature DB >> 20466975

Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion.

Michelle A Fryirs1, Philip J Barter, Mathiyalagan Appavoo, Bernard E Tuch, Fatiha Tabet, Alison K Heather, Kerry-Anne Rye.   

Abstract

OBJECTIVE: Type 2 diabetes is characterized by impaired beta-cell secretory function, insulin resistance, reduced high-density lipoprotein (HDL) levels, and increased cardiovascular risk. Given the current interest in therapeutic interventions that raise HDLs levels, this study investigates the effects of HDLs on insulin secretion from beta-cells. METHODS AND
RESULTS: Incubation of Min6 cells and primary islets under basal or high-glucose conditions with either apolipoprotein (apo) A-I or apoA-II in the lipid-free form, as a constituent of discoidal reconstituted HDLs (rHDLs), or with HDLs isolated from human plasma increased insulin secretion up to 5-fold in a calcium-dependent manner. The increase was time and concentration dependent. It was also K(ATP) channel and glucose metabolism dependent under high-glucose, but not low-glucose, conditions. The lipid-free apolipoprotein-mediated increase in insulin secretion was ATP binding cassette (ABC) transporter A1 and scavenger receptor-B1 dependent. The rHDL-mediated increase in insulin secretion was ABCG1 dependent. Exposure of beta-cells to lipid-free apolipoproteins also increased insulin mRNA expression and insulin secretion without significantly depleting intracellular insulin or cholesterol levels.
CONCLUSIONS: These results establish that lipid-free and lipid-associated apoA-I and apoA-II increase beta-cell insulin secretion and indicate that interventions that raise HDLs levels may be beneficial in type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20466975     DOI: 10.1161/ATVBAHA.110.207373

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  92 in total

1.  Association between ABCG1 polymorphism rs1893590 and high-density lipoprotein (HDL) in an asymptomatic Brazilian population.

Authors:  V H S Zago; D Z Scherrer; E S Parra; N B Panzoldo; F Alexandre; E R Nakandakare; E C R Quintão; E C de Faria
Journal:  Mol Biol Rep       Date:  2014-11-15       Impact factor: 2.316

Review 2.  Genetics of cholesterol efflux.

Authors:  Iulia Iatan; Aurélien Palmyre; Sarah Alrasheed; Isabelle Ruel; Jacques Genest
Journal:  Curr Atheroscler Rep       Date:  2012-06       Impact factor: 5.113

3.  Plasma lipid levels predict dysglycemia in a biracial cohort of nondiabetic subjects: Potential mechanisms.

Authors:  Ibiye Owei; Nkiru Umekwe; Jim Wan; Samuel Dagogo-Jack
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-17

Review 4.  The emerging role of HDL in glucose metabolism.

Authors:  Brian G Drew; Kerry-Anne Rye; Stephen J Duffy; Philip Barter; Bronwyn A Kingwell
Journal:  Nat Rev Endocrinol       Date:  2012-01-24       Impact factor: 43.330

Review 5.  Cardioprotective functions of HDLs.

Authors:  Kerry-Anne Rye; Philip J Barter
Journal:  J Lipid Res       Date:  2013-06-27       Impact factor: 5.922

6.  APOL1 nephropathy risk variants are associated with altered high-density lipoprotein profiles in African Americans.

Authors:  Orlando M Gutiérrez; Suzanne E Judd; Marguerite R Irvin; Degui Zhi; Nita Limdi; Nicholette D Palmer; Stephen S Rich; Michèle M Sale; Barry I Freedman
Journal:  Nephrol Dial Transplant       Date:  2015-07-06       Impact factor: 5.992

7.  High-density lipoprotein maintains skeletal muscle function by modulating cellular respiration in mice.

Authors:  Maarit Lehti; Elizabeth Donelan; William Abplanalp; Omar Al-Massadi; Kirk M Habegger; Jon Weber; Chandler Ress; Johannes Mansfeld; Sonal Somvanshi; Chitrang Trivedi; Michaela Keuper; Teja Ograjsek; Cynthia Striese; Sebastian Cucuruz; Paul T Pfluger; Radhakrishna Krishna; Scott M Gordon; R A Gangani D Silva; Serge Luquet; Julien Castel; Sarah Martinez; David D'Alessio; W Sean Davidson; Susanna M Hofmann
Journal:  Circulation       Date:  2013-10-29       Impact factor: 29.690

8.  Apolipoprotein A-II alters the proteome of human lipoproteins and enhances cholesterol efflux from ABCA1.

Authors:  John T Melchior; Scott E Street; Allison B Andraski; Jeremy D Furtado; Frank M Sacks; Rebecca L Shute; Emily I Greve; Debi K Swertfeger; Hailong Li; Amy S Shah; L Jason Lu; W Sean Davidson
Journal:  J Lipid Res       Date:  2017-05-05       Impact factor: 5.922

Review 9.  The physiological roles of apolipoprotein J/clusterin in metabolic and cardiovascular diseases.

Authors:  S Park; K W Mathis; I K Lee
Journal:  Rev Endocr Metab Disord       Date:  2014-03       Impact factor: 6.514

10.  In vivo PET imaging with [(18)F]FDG to explain improved glucose uptake in an apolipoprotein A-I treated mouse model of diabetes.

Authors:  Blake J Cochran; William J Ryder; Arvind Parmar; Shudi Tang; Anthonin Reilhac; Andrew Arthur; Arnaud Charil; Hasar Hamze; Philip J Barter; Leonard Kritharides; Steven R Meikle; Marie-Claude Gregoire; Kerry-Anne Rye
Journal:  Diabetologia       Date:  2016-05-18       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.